Delivery Order SPE2DB22D1106-SPE2DB25FEGQ4

Award Date 4/7/25
Potential Completion Date 4/8/25
Potential Value $47K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $7,092.04, is a delivery order for the supply of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of April 3, 2025 and is a firm fixed-price contract. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,429.98, is for the delivery of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order, with a period of performance ending on January 7, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $37,078.52 delivery order contract is for the supply of RINVOQ ER 45 MG TABLET, a prescription medication. The contract is a firm fixed-price, non-set-aside award with a performance period through May 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,095.90, is for the delivery of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and has an ultimate completion date of February 28, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of RINVOQ ER 15 MG TABLET UU 30S. The $46,877.89 firm fixed-price delivery order has a completion date of February 14, 2025 and is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a $41,420.77 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract covers the supply of RINVOQ ER 30 MG TABLET UU 30S, a specialty medication, to support federal healthcare programs. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $25,121.21, is a delivery order for the supply of RINVOQ ER 15 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of March 4, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RINVOQ ER 45 MG TABLET UU 28S, a pharmaceutical product, with a ceiling value of $71,764.96 and a period of performance through March 31, 2025. The contract was awarded as a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,113.48, is for the delivery of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 6, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,407.38, is for the delivery of RINVOQ ER 30 MG TABLET UU 30S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of April 2, 2025. There is no set-aside designation indicated for this award. AmerisourceBergen...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FEGQ4
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 MG TABLET UU 30S. The contract is a delivery order with a firm fixed price of $46,682.44 and a period of performance through April 8, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 7/7/25, 1:19 PM